Immatics Nv Stock Today
| IMTX Stock | USD 7.58 0.22 2.82% |
Performance0 of 100
| Odds Of DistressLess than 23
|
Immatics is trading at 7.58 as of the 22nd of November 2024; that is 2.82 percent down since the beginning of the trading day. The stock's open price was 7.8. Immatics has about a 23 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for Immatics NV are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of May 2024 and ending today, the 22nd of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 2nd of July 2020 | Category Healthcare | Classification Health Care |
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor based immunotherapies for the treatment of cancer in the United States. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers and Genmab AS to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. The company has 121.55 M outstanding shares of which 6.69 M shares are currently shorted by private and institutional investors with about 8.76 trading days to cover. More on Immatics NV
Moving together with Immatics Stock
Moving against Immatics Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Immatics Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsImmatics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Immatics' financial leverage. It provides some insight into what part of Immatics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Immatics NV (IMTX) is traded on NASDAQ Exchange in USA. It is located in Paul-Ehrlich-Strasse 15, Tübingen, Germany, 72076 and employs 542 people. Immatics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 948.09 M. Immatics NV conducts business under Biotechnology sector and is part of Health Care industry. The entity has 121.55 M outstanding shares of which 6.69 M shares are currently shorted by private and institutional investors with about 8.76 trading days to cover.
Immatics NV currently holds about 324.38 M in cash with 18.23 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.0.
Check Immatics Probability Of Bankruptcy
Ownership AllocationImmatics NV has a total of 121.55 Million outstanding shares. Over half of Immatics' outstanding shares are owned by outside corporations. These outside corporations are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Immatics Ownership Details
Immatics Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Ra Capital Management, Llc | 2024-06-30 | 1.8 M | |
| Braidwell Lp | 2024-09-30 | 1.6 M | |
| Nantahala Capital Management, Llc | 2024-06-30 | 1.6 M | |
| Suvretta Capital Management, Llc | 2024-06-30 | 946.6 K | |
| Citadel Advisors Llc | 2024-06-30 | 885.4 K | |
| Wasatch Advisors Lp | 2024-06-30 | 843.3 K | |
| 683 Capital Management Llc | 2024-06-30 | 815 K | |
| Sofinnova Ventures | 2024-06-30 | 796.7 K | |
| Adage Capital Partners Gp Llc | 2024-06-30 | 751.3 K | |
| Rtw Investments, Llc | 2024-06-30 | 10 M | |
| Wellington Management Company Llp | 2024-06-30 | 9.5 M |
Immatics Historical Income Statement
Immatics Stock Against Markets
Immatics Corporate Management
| Andrea Mokler | VP Sciences | Profile | |
| Miriam Meyer | VP Affairs | Profile | |
| PHR MBA | Director HR | Profile | |
| Edward Sturchio | General Secretary | Profile | |
| Arnd MBA | Chief Officer | Profile | |
| Toni Weinschenk | CoFounder Officer | Profile |
Additional Tools for Immatics Stock Analysis
When running Immatics' price analysis, check to measure Immatics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics is operating at the current time. Most of Immatics' value examination focuses on studying past and present price action to predict the probability of Immatics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immatics' price. Additionally, you may evaluate how the addition of Immatics to your portfolios can decrease your overall portfolio volatility.